1,169 code entries across 838 active EviCore by Evernorth policies that Backwork has recorded as requiring prior authorization. Each policy links to its page and to the payer’s source.
Summary of the payer’s published policy. Not a coverage determination — confirm with EviCore by Evernorth before submitting.
401–450 of 838, by title
Codes labeled “Inferred from policy title” are not listed in the policy document; Backwork attached them because the policy title names the drug.
| Policy | Effective | Codes requiring prior authorization |
|---|---|---|
| Lanreotide (Somatuline Depot, generic) Injection-non oncology | Not recorded |
| Lanreotide (Somatuline Depot) | Sep 1, 2019 |
|---|
| Lanreotide (Somatuline Depot) | Jan 1, 2019 |
|---|
| Lanreotide (Somatuline Depot) | Jun 1, 2022 |
|---|
| Lanreotide (Somatuline Depot) | Jun 1, 2023 |
|---|
| Lanreotide (Somatuline Depot) | Jul 1, 2021 |
|---|
| Lanreotide (Somatuline Depot) | Aug 1, 2020 |
|---|
| Laronidase (Aldurazyme) | Jul 1, 2023 |
|
|---|
| Laronidase (Aldurazyme) | Aug 1, 2021 |
|
|---|
| Laronidase (Aldurazyme) | Jan 1, 2019 |
|
|---|
| Laronidase (Aldurazyme) | Jul 1, 2022 |
|
|---|
| Laronidase (Aldurazyme) | Oct 1, 2019 |
|
|---|
| Laronidase (Aldurazyme) | Sep 1, 2020 |
|
|---|
| Lemtrada (alemtuzumab) | May 1, 2024 |
|
|---|
| Lemtrada (alemtuzumab) | May 1, 2025 |
|
|---|
| Lemtrada (alemtuzumab) | Not recorded |
|
|---|
| Leqembi (lecanemab-irmb) | May 1, 2025 |
|
|---|
| Leqembi (lecanemab-irmb) | May 1, 2024 |
|
|---|
| Leqembi (lecanemab-irmb) | Not recorded |
|
|---|
| Leqembi (lecanemab) | Jun 1, 2023 |
|
|---|
| Leqvio (inclisiran subcutaneous injection) | Sep 1, 2024 |
|
|---|
| Leqvio (inclisiran subcutaneous injection) | Not recorded |
|
|---|
| Leqvio (inclisiran subcutaneous injection) | Sep 1, 2025 |
|
|---|
| Leqvio (inclisiran subcutaneous injection) | Feb 1, 2026 |
|
|---|
| Leqvio (inclisiran) | Sep 1, 2023 |
|
|---|
| Leuprolide Acetate (Fensolvi, Lupron Depot- PED, Lupron Depot) | Dec 1, 2022 |
|
|---|
| Leuprolide Acetate (Fensolvi, Lupron Depot- PED, Lupron Depot) | Jan 1, 2022 |
|
|---|
| Leuprolide Acetate (Fensolvi, Lupron Depot- PED, Lupron Depot) | Feb 1, 2021 |
|
|---|
| Leuprolide acetate (Fensolvi, Lupron Depot-PED, Lupron Depot) Non-oncology | Nov 1, 2025 |
|
|---|
| Leuprolide acetate (Fensolvi, Lupron Depot-PED, Lupron Depot) Non-oncology | Nov 1, 2024 |
|
|---|
| Leuprolide acetate (Fensolvi, Lupron Depot-PED, Lupron Depot)_Non-onc | Nov 1, 2023 |
|
|---|
| Leuprolide acetate (Fensolvi, Lupron Depot-PED, Lupron Depot)_Non-onc | Nov 1, 2024 |
|
|---|
| Leuprolide Acetate (Fensolvi) | Sep 1, 2020 |
|---|
| Lumasiran (Oxlumo) | Mar 1, 2022 |
|
|---|
| Lumasiran (Oxlumo) | Feb 1, 2023 |
|
|---|
| Lumasiran (Oxlumo) | Apr 1, 2023 |
|
|---|
| Lumizyme (alglucosidase alfa) | Not recorded |
|
|---|
| Lumizyme (alglucosidase alfa) | Jul 1, 2024 |
|
|---|
| Lumizyme (alglucosidase alfa) | Jul 1, 2025 |
|
|---|
| Luspatercept-aamt (Reblozyl) | Mar 1, 2020 |
|
|---|
| Luspatercept-aamt (Reblozyl) | Jan 1, 2023 |
|
|---|
| Luspatercept-aamt (Reblozyl) | Feb 1, 2022 |
|
|---|
| Luspatercept-aamt (Reblozyl) | Mar 15, 2021 |
|
|---|
| Mepolizumab (Nucala) | May 1, 2022 |
|
|---|
| Mepolizumab (Nucala) | Aug 1, 2019 |
|
|---|
| Mepolizumab (Nucala) | Jan 1, 2020 |
|
|---|
| Mepolizumab (Nucala) | Jun 1, 2021 |
|
|---|
| Mepolizumab (Nucala) | May 15, 2018 |
|
|---|
| Mepolizumab (Nucala) | Aug 1, 2018 |
|
|---|
| Mepolizumab (Nucala) | Jul 1, 2020 |
|
|---|